Fate Therapeutics, Inc. ( NASDAQ:FATE – Get Free Report ) has received an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $5.90.
A number of research firms recently issued reports on FATE. Wells Fargo & Company lifted their price target on shares of Fate Therapeutics from $2.50 to $3.50 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Fate Therapeutics in a research report on Friday, August 7th. Piper Sandler reaffirmed an “overweight” rating and set a $8.00 price objective (up from $6.00) on shares of Fate Therapeutics in a report on Friday, August 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of Fate Therapeutics in a research report on Tuesday, October 27th.
Institutional Inflows and Outf...